GREGORJ, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 438
EU - Europa 144
AS - Asia 93
SA - Sud America 3
OC - Oceania 1
Totale 679
Nazione #
US - Stati Uniti d'America 435
IN - India 42
SE - Svezia 39
CN - Cina 36
UA - Ucraina 30
FI - Finlandia 22
IT - Italia 22
SG - Singapore 15
RO - Romania 8
DE - Germania 7
IE - Irlanda 7
GB - Regno Unito 4
BE - Belgio 3
AR - Argentina 2
CA - Canada 2
CL - Cile 1
ES - Italia 1
MX - Messico 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
Totale 679
Città #
Fairfield 47
Chandler 42
Des Moines 36
Ann Arbor 35
Beijing 32
Ashburn 23
Wilmington 23
Boston 22
Plano 22
Princeton 22
San Paolo di Civitate 16
Seattle 15
Woodbridge 14
Houston 12
Boardman 10
Lawrence 9
Cambridge 8
Jacksonville 7
Andover 6
Dublin 6
Norwalk 6
San Diego 5
Singapore 5
Brussels 3
Bühl 3
Rome 3
San Mateo 3
Southend 3
Bremen 2
Catania 2
Dearborn 2
Federal 2
Hefei 2
Toronto 2
Athy 1
Auckland 1
Buffalo 1
Falls Church 1
Guangzhou 1
Kunming 1
Las Vegas 1
London 1
Madrid 1
St Louis 1
Trumbull 1
Totale 461
Nome #
Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells. 57
Protein expression of p15 and p21 plays an unfavorable prognostic role in adult acute lymphoblastic leukemia (ALL) patients independently of their gene promoter methylation status. 55
Apoptosis susceptibility and cell-cycle distribution in cells from myelodysplastic syndrome patients: modulatory in-vitro effects of G-CSF and Interferon-alpha 48
Functional effects of the Bcl-2/Bcl-xL inhibitor ABT-737 on primary cells from smoldering multiple myeloma. 45
Higher spontaneous rate of apoptosis characterizes myelodysplastic syndromes at lower risk of leukemic evolution. 39
Differential regulation of p27 and cyclins between bone marrow and mobilized peripheral blood CD34+ cells. 38
Leucemie linfoidi acute dell’adulto: Fattori di crescita. 37
Prostaglandine E1 and erythropoietin on primary cells from myelodysplastic patients: divergent apoptotic effects between low and high risk patients. 33
Expression of the cyclin-dependent kinase inhibitor p27 in leukemias. 30
High levels of apoptosis characterize RAEB and are lost during leukemic transformation. 29
Functional effects of the bcl-2/bcl-xl inhibitor abt-737 on primary cells from smoldering and symptomatic multiple myeloma. 29
Multiple Strategies Based on MEK, mTOR and BCL-2 Signal Transduction Inhibition in Acute Lymphoblastic Leukemia (ALL). 27
Apoptosis is a prognostic factor for disease progression in chronic lymphocytic leukemia 27
The Bcl-2 antagonist ABT-737 is highly effective on primary acute lymphoblastic leukemia cells. 26
Susceptibility to apoptosis and p27KIP1 expression in stable and progressive chronic lymphocytic leukemia. 24
The Bcl-2 antagonist ABT-737 is highly effective on primary acute lymphoblastic leukemia cells. 24
Molecular control of normal and neoplastic hemopoiesis: role of the cyclin-dependent kinase inhibitor p27 23
IL-6 receptor super-antagonists 21
Stable disease in chronic lymphocytic leukemia is characterized by p27 overexpression and a higher susceptibility to enter apoptosis. 20
Stable disease in chronic lymphocytic leukemias is associated with enhanced levels of apoptosis 19
CD34+ cells in myelodysplastic syndromes with lower percentage of blasts are characterized by high spontaneous rate of apoptosis. 16
Ci sono controindicazioni all’uso del G-CSF nelle mobilizzazioni di PBSC autologhe in oncoematologia? 15
Totale 682
Categoria #
all - tutte 1.919
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.919


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20199 0 0 0 0 0 0 0 0 0 0 5 4
2019/2020117 24 1 0 3 6 8 9 12 7 24 18 5
2020/202150 1 8 0 9 4 0 5 10 4 2 7 0
2021/2022171 1 10 14 11 33 1 0 16 12 14 13 46
2022/2023215 41 36 3 26 23 48 7 5 17 0 8 1
2023/202460 7 7 6 13 7 0 1 0 0 10 9 0
Totale 682